All In Biotech

Drug Trial Radar · NCT07712939

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

A Phase 1, First-In-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CND319 in Healthy Participants and Patients With Rheumatic Diseases

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Jul 22, 2026

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Candid TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.

Conditions

  • Healthy Participants Study
  • Rheumatoid Arthritis
  • Sjogren's Syndrome

Interventions

  • CND319Biological

    CND319

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence proportion and severity of treatment-emergent adverse events through end of studyTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
  2. Changes to body temperatureTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
  3. Changes to heart rateTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
  4. Changes to respiratory rateTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
  5. Changes to blood pressureTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
  6. Changes to pulse oximetryTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
  7. Changes from baseline in ECG parameters through end of study: PR intervalTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
  8. Changes from baseline in ECG parameters through end of study: QRS intervalTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
  9. Changes from baseline in ECG parameters through end of study: QT intervalTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
  10. Changes from baseline in safety laboratory assessments through end of studyTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Candid Clinical Site

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.